The post How Early Detection Helped Maria Menounos Against Pancreatic Cancer appeared on BitcoinEthereumNews.com. Maria Menounos, whose went through surgery in 2017 to remove a meningioma and in 2023 to remove a neuroendocrine cacner of her pancreas,hosts a podcast called the Heal Squad. (Photo: Lemieux Creative LLC 2021) Lemieux Creative LLC 2021 You may not care if the early bird gets the worm, if you happen to not like worms. But early detection of cancer will get you something you should definitely want: much higher chances of successful treatment. That’s what happened to Emmy Award-winning TV host, author and podcaster Maria Menounos when the neuroendocrine cancer that she had in her pancreas was detected before it could spread any further. You could say that harrowing experience has pan-created motivation for Menounos to team up with Exact Sciences—the makers of a multi-cancer screening blood test called Cancerguard— to advocate for more cancer screening. I recently talked to Menounous, who’s been a host of Entertainment Tonight, Access Hollywood, and E! News and a reporter for The Today Show, about all this and more. Menounos Had A Meningioma Removed In 2017 Part of the more is that Menounos has now seen cancer from different perspectives. In 2016, her mother, Litsa Menounos, was diagnosed with a malignant and very difficult to treat type of brain cancer known as glioblastoma multiforme, which originates from the glial cells of the brain. As she cared for her mother going through radiation and chemotherapy treatments, Menounos started experiencing brain-ish symptoms herself: intense ear pain, headaches, dizziness and slurred speech. Her doctor ordered an MRI of the brain, but Menounos, given her busy TV schedule including serving as the co-anchor of E! News, postponed getting it. But that led to even more EEEE! news—she began having blurry vision. That prompted her to clearly see the need to get the MRI, which she finally… The post How Early Detection Helped Maria Menounos Against Pancreatic Cancer appeared on BitcoinEthereumNews.com. Maria Menounos, whose went through surgery in 2017 to remove a meningioma and in 2023 to remove a neuroendocrine cacner of her pancreas,hosts a podcast called the Heal Squad. (Photo: Lemieux Creative LLC 2021) Lemieux Creative LLC 2021 You may not care if the early bird gets the worm, if you happen to not like worms. But early detection of cancer will get you something you should definitely want: much higher chances of successful treatment. That’s what happened to Emmy Award-winning TV host, author and podcaster Maria Menounos when the neuroendocrine cancer that she had in her pancreas was detected before it could spread any further. You could say that harrowing experience has pan-created motivation for Menounos to team up with Exact Sciences—the makers of a multi-cancer screening blood test called Cancerguard— to advocate for more cancer screening. I recently talked to Menounous, who’s been a host of Entertainment Tonight, Access Hollywood, and E! News and a reporter for The Today Show, about all this and more. Menounos Had A Meningioma Removed In 2017 Part of the more is that Menounos has now seen cancer from different perspectives. In 2016, her mother, Litsa Menounos, was diagnosed with a malignant and very difficult to treat type of brain cancer known as glioblastoma multiforme, which originates from the glial cells of the brain. As she cared for her mother going through radiation and chemotherapy treatments, Menounos started experiencing brain-ish symptoms herself: intense ear pain, headaches, dizziness and slurred speech. Her doctor ordered an MRI of the brain, but Menounos, given her busy TV schedule including serving as the co-anchor of E! News, postponed getting it. But that led to even more EEEE! news—she began having blurry vision. That prompted her to clearly see the need to get the MRI, which she finally…

How Early Detection Helped Maria Menounos Against Pancreatic Cancer

2025/11/16 21:07

Maria Menounos, whose went through surgery in 2017 to remove a meningioma and in 2023 to remove a neuroendocrine cacner of her pancreas,hosts a podcast called the Heal Squad. (Photo: Lemieux Creative LLC 2021)

Lemieux Creative LLC 2021

You may not care if the early bird gets the worm, if you happen to not like worms. But early detection of cancer will get you something you should definitely want: much higher chances of successful treatment. That’s what happened to Emmy Award-winning TV host, author and podcaster Maria Menounos when the neuroendocrine cancer that she had in her pancreas was detected before it could spread any further. You could say that harrowing experience has pan-created motivation for Menounos to team up with Exact Sciences—the makers of a multi-cancer screening blood test called Cancerguard— to advocate for more cancer screening. I recently talked to Menounous, who’s been a host of Entertainment Tonight, Access Hollywood, and E! News and a reporter for The Today Show, about all this and more.

Menounos Had A Meningioma Removed In 2017

Part of the more is that Menounos has now seen cancer from different perspectives. In 2016, her mother, Litsa Menounos, was diagnosed with a malignant and very difficult to treat type of brain cancer known as glioblastoma multiforme, which originates from the glial cells of the brain. As she cared for her mother going through radiation and chemotherapy treatments, Menounos started experiencing brain-ish symptoms herself: intense ear pain, headaches, dizziness and slurred speech. Her doctor ordered an MRI of the brain, but Menounos, given her busy TV schedule including serving as the co-anchor of E! News, postponed getting it. But that led to even more EEEE! news—she began having blurry vision. That prompted her to clearly see the need to get the MRI, which she finally did at 10:30 pm on a Friday at UCLA Medical Center, because what else are you going to do on a Friday night.

The MRI revealed a meningioma about the size of a golf-ball. So both she and her mother had brain tumors, which was kind of WTF coincidence. But their tumors were different. A meningioma is a growth from the meninges, membranes that wrap around your brain like Saran Wrap around a fruitcake. And unlike GBMs, menigiomas are typically benign since they tend to be so slow growing.

However, that doesn’t mean you can just ignore it like a bad mullet (as opposed to a good mullet). Depending on its location and where it grows, a meningioma can press upon vital structures in the brain and cause all sorts of problems. She eventually underwent surgery to remove the meningioma and for a while had to deal with the after effects of the surgery. The whole experience taught Menounous to be pay more attention to her health.

Menounos Began Experiencing Unexplained Symptoms In 2022

Maria Menounos speaks at Fran Drescher’s Cancer Schmancer Health Summit at The Music Center on April 20, 2024 in Los Angeles, California. (Photo by Corine Solberg/Getty Images)

Getty Images

Fast forward to 2022 when she started experiencing bloating and substantial pain in the left upper quadrant of her abdomen. “I remember like all of 2022 trying to figure out what was going on,” she recalled. “I was taking photos in the mirror. I had this big, like, where is this coming from?”

She continued by saying, “So I went to the doctor, then we did additional tests like endoscopy and colonoscopy, but nothing was coming back to explain these pains. And then the pains got worse, they got really, really bad, and then I got a CT scan and that said, I was clear, too.”

But it still wasn’t clear what was causing these symptoms. “It wasn’t until I basically took matters into my own hands and did some additional screening that I found this rare form of pancreatic cancer,” she explained. A full body MRI in 2023 revealed cancer in her pancreas.

Menounos Had A Rare Type Of Pancreatic Cancer

Her mother had recently passed away from the brain cancer and now Menounos thought she herself was a “goner.” She had heard that people don’t tend to survive too long after getting diagnosed with pancreatic cancer. But rather than the more common adenocarcinoma of the pancreas that arise from the cells lining the pancreatic ducts this was a neuroendocrine cancer arising from the hormone-producing cells of the pancreas. Plus, it was still at stage 2, meaning that it hadn’t yet spread to the lymph nodes and beyond. That made it more likely to be completely removed by surgery.

When it comes to surgery, the joke is that the only minor surgery for you is when it is on someone else. But surgery for pancreatic cancer is especially major and grueling. The pancreas is tucked deep among various vital structures in your abdomen. So, cutting out part of pancreas involves rearranging things in there. The surgery did manage to get the mass out along with her surrounding lymph nodes and spleen as well as a big ol’ fibroid. “Fortunately, they found that the tumor was still confined within the pancreas,” she told me. “They had like removed 17 lymph nodes. It was a long surgery.” In this case, long meant around 10 hours, which is longer than it would take to watch the entire Lord of the Rings trilogy.

For Menounos, Early Detection Was Key

What was even longer was recovery from the surgery. “Yeah, it took a minute,” she remarked tongue-in-cheek figuratively and not literally. “I was lucky that they got it all out and it hadn’t spread anywhere.” As a result, Menounos was able to welcome along with her husband Keven Undergaro the arrival of their daughter Athena via a surrogate that year. Menounos had to recover from the grueling surgery, which ain’t easy, and she has to continue to go through regular testing to make sure things are OK. You could say that Menounos—who has also made various appearance with World Wrestling Entertainment, co-hosting WWE Raw and even getting into the ring herself— has certainly wrestled with some major health issues over the past decade. Nonetheless, she said, “I’m really blessed because if I hadn’t gone through the additional screenings, I might not be here right now.”

Menounos Hosts The Heal Squad Podcast

All of these experiences made it natural for her to do two things. One is to host a podcast called Heal Squad. This is where she discusses her and others’ health journeys and helps people how to advocate for themselves through this Jumanji-esque jungle known as the U.S. healthcare system. “Even with really well-intentioned doctors, the system is set up, unfortunately, to help you when you’re already sick,” she lamented. “They’re not set up to really really be preventative, and this is why I’m so passionate about teaching people to be the CEO of their health and to take control of their health, because you have to be the one that’s doing the preventative measures with your diet, with your sleep habits, with your circadian function habits, with everything, and then especially with expanded screenings.”

Menounos Is Working With Exact Sciences

The other thing she has done is to connect with Exact Sciences to advocate for expanded cancer screening, because in here words, “70% of annual cancers and deaths in this country don’t have any routine recommended cancer screenings, and so things like pancreatic cancer, or lung cancer, esophageal, stomach cancer, these have the highest morbidity risks and are the most deadliest cancers, and we haven’t have any regular screenings for them.” I’ve written before in Forbes about how Exact Sciences makes Cologuard, a test used to screen your poop for colon cancer. But in the end, that’s not all that Exact Sciences does. At the beginning of this article, I mentioned that the company also makes Cancerguard, a blood test that can be used to screen for the presence of biomarkers associated with over 50 different types and subtypes of cancer. Included in this 50 are many cancers for which there aren’t currently other types of routine screening methods like liver, pancreatic, ovarian, gastric and esophageal cancer.

The test certainly isn’t perfect. It has an overall sensitivity of around 64%, which means that if you have one of the 50 cancers it will pick it up 64% of the time, as reported by Angus Chen for STAT News. However, this sensitivity does fall down to 39% when focusing on earlier stage—like stage 1 or 2—cancers. Of course, 39% still is a lot better than 0%, which may your chance of detecting cancers deep in your body like pancreatic cancer in their early stages when you don’t do any type of routine screening for them.

For years, there have been traditional and widely used routine screening methods for only a limited number of cancer—namely breast, prostate, skin, colon and lung. Having multi-cancer early detection tests like Cancerguard and Grail’s Galleri test now on the market could help significantly expand what cancers you are trying to catch early on before they’s spread too far. It is still early days for such tests so we’ll have to see how widely available and accepted they become and how such tests perform over the long run. But you don’t have to look too hard to see the many clear benefits of being able to detect cancer early.

Source: https://www.forbes.com/sites/brucelee/2025/11/16/how-early-detection-helped-maria-menounos-against-pancreatic-cancer/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Understanding the Ethereum Interoperability Layer (EIL): Bridging L2 Fragmentation and Building a Seamless Cross-Chain Experience

Understanding the Ethereum Interoperability Layer (EIL): Bridging L2 Fragmentation and Building a Seamless Cross-Chain Experience

Author: Pan Zhixiong Ethereum has successfully addressed the scaling issue over the past few years by deploying multiple Layer 2 solutions, such as Arbitrum, Optimism, and Base, resulting in reduced transaction costs and increased efficiency. However, this has led to a fragmented user experience: each L2 network acts like an isolated island, with users facing cumbersome steps, different bridging protocols, and complex asset and gas management when crossing chains. To address this pain point, the Ethereum core team recently proposed the Ethereum Interop Layer (EIL). To understand EIL, we first need to review its foundation—ERC-4337. ERC-4337 is an account abstraction standard proposed by Ethereum. It requires no changes to the underlying Ethereum protocol, implementing a new type of account structure—the smart account—simply by deploying smart contracts. This type of account not only supports advanced features such as social recovery, multisignature, and batch operations, but also allows for gas payments using ERC-20 tokens via smart contracts. However, despite the many technological innovations brought by ERC-4337, its adoption in practice remains limited. Fragmented user experience, difficulties in multi-chain collaboration, high gas costs, and ecosystem compatibility issues all restrict the widespread adoption of 4337. The EIL was developed to address these issues on top of ERC-4337. EIL is an additional multi-chain interoperability protocol built upon the ERC-4337 framework . It extends the single-chain account abstraction to multi-chain account interoperability, enabling a seamless experience across multiple L2 networks. Specifically, EIL implements two important innovations: one-signature multi-chain operations (bulk authorization) and a competitive funding mechanism for cross-chain liquidity providers (XLPs). The first innovation, bulk authorization , allows users to authorize multiple operations across multiple L2 networks with a single signature. Specifically, the wallet first constructs its own UserOperation on each relevant chain, then integrates these operations into a Merkle tree. Users only need to sign the root of the tree once. When a smart account on each chain verifies a received UserOperation, it only needs to verify that it belongs to the Merkle tree and that the signature is valid to execute the operation. This approach significantly simplifies the cross-chain operation process for users. The second innovation, the auction-based funding mechanism, introduces a role called Cross-chain Liquidity Provider (XLP). XLPs are responsible for providing asset transfer and gas payment services between different chains. When a user locks assets on the source chain and submits a cross-chain request, multiple XLPs can bid on the request through on-chain auction. The XLP that wins the bid provides a cross-chain asset transfer voucher, allowing the user to directly obtain funds and gas payments on the target chain to complete the required cross-chain operation. Only after the transaction is completed will the XLP claim the user's previously locked assets on the source chain. To ensure security and fairness, XLPs must be staked on the Ethereum mainnet (L1) and subject to a strict dispute arbitration mechanism. If an XLP violates the rules, the staked assets will be forfeited, thus ensuring its integrity through economic incentives . It's worth emphasizing that EIL doesn't require any changes to the consensus protocol of the Ethereum mainnet or L2 network during its implementation . All implementations are based on smart contracts and the existing ERC-4337 account abstraction framework. This design not only reduces the difficulty of implementation but also significantly reduces the security risks the chain itself may face. Of course, this design also shifts the pressure and complexity to the wallet and off-chain infrastructure . The wallet needs to support complex multi-chain transaction construction, one-signature multi-chain verification, interaction mechanisms with CrossChainPaymaster and XLP, and needs to provide a simple and user-friendly interface. The off-chain infrastructure, on the other hand, needs to build a robust auction market, monitor XLP fund flows in real time, and manage risks. Ultimately, EIL provides users with a single-chain-like experience. In the future, when users open EIL-enabled wallets, they will no longer need to frequently switch chains, manage cross-chain assets, or endure lengthy cross-chain waits and cumbersome procedures. All complex cross-chain details will be completed automatically outside the user's view, gradually unifying the user experience across the entire Ethereum L2 ecosystem and truly realizing the vision of multi-chain integration and seamless interoperability. EIL also opens up a whole new possibility for the entire Ethereum ecosystem: it not only solves the cross-chain user experience problem, but more importantly, it truly allows multiple L2 networks to "become one" in a secure, decentralized, and trustless way.
Share
PANews2025/11/21 14:00